Evotec SE : Massive warning on FY 2024 – downgrade to Neutral
>Adj. EBITDA guidance down by approx. 75% - When the company published its 2023 financial figures on 24 April 2024 the company guided low double-digit percentage sales growth in 2024 (indicating at least € 860m) and a mid-double digit percentage adj. EBITDA growth (indicating approx. € 99m). Already this guidance was significantly below market expectations and led to a cut in our 2024 sales estimates of 8% to € 860m and a 34% cut of our adj. EBITDA estimates to € 103m...Evotec is a holding company engaged as a drug discovery solutions company providing drug discovery capabilities to pharmaceutical and biotechnology companies as well as to academic institutions. These drug discovery solutions are provided in form of fee-for service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Co. is primarily involved in the areas of neuroscience, pain, metabolic diseases, oncology and inflammation. Co. provides its drug discovery activities under the banners of EVT Execute, EVT Integrate and EVT Innovate. Co.'s operations are divided into two segments: EVT Execute and EVT Innovate.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.